NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

NeoStem Story

NeoStem’s story begins with the simple idea that we can use modern science to harness and enhance the healing mechanisms that already exist inside our own bodies. NeoStem is leading the paradigm shift in modern medicine towards cell therapy – a shift away from treating disease with drugs and toward treating disease with the body’s own cells. Just as the cell therapy industry has grown and developed over the past decade, NeoStem too has transformed itself through a series of strategic mergers and acquisitions. NeoStem acquired PCT, a market-leading contract development and manufacturing company, in 2011 and gained access for its product candidates to PCT’s world-class development expertise and manufacturing capabilities, as well as to a unique platform offering experience with multiple cell types. Also in 2011, NeoStem acquired the technologies for its Ischemic Repair Program and Immune Modulation Program, expanding the Company’s development pipeline. In 2014 NeoStem’s pipeline expanded further with its acquisition of California Stem Cell, Inc., creating the Company’s Targeted Cancer Immunotherapy Program and beginning NeoStem’s investigation into cancer therapeutics. Today, NeoStem leverages its center of innovation and excellence in cell therapy (PCT) to support product development and manufacture for clients ranging from emerging biotech to big pharma as well as across multiple internal development programs, and with each new clinical and regulatory milestone we and our peers in the industry achieve, our passion and excitement about the potential for cell therapy grows.

Key Milestones


2015

  • NeoStem Receives Drug Manufacture License for Irvine Facility Learn More »
  • NeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing Learn More »

2014

  • NeoStem acquires California Stem Cell, Inc., developing NeoStem’s Targeted Cancer Immunotherapy Program. Learn More »
  • Begins research collaboration for treatment of skin wounds in scleroderma Learn More »
  • Announced second research collaboration with Mass. Eye and Ear/Schepens Eye Research Institute exploring NeoStem’s VSEL™ Technology for retinal repair Learn More »
  • Expanded Treg international patent portfolio with granting of patent in Japan Learn More »
  • Expanded CD34 cell patent portfolio with new US and European patent allowances Learn More »

2013

  • Completed patient enrollment in Phase 2 AMR-001 trial for prevention of adverse cardiovascular events following a heart attack. Learn More »
  • NeoStem ranked #1 fastest growing company in Tri-State region on Deloitte’s 2012 Technology Fast 500™ for second year in a row. Learn More »
  • NeoStem begins trading on NASDAQ stock market. Learn More »
  • Advances autoimmune platform through UCSF collaboration. Learn More »
  • Held Second International Vatican Adult Stem Cell Conference, in partnership with the Vatican’s Pontifical Council for Culture in April. Learn More »
  • Further expansions of NeoStem’s cardiovascular disease intellectual property coverage. Learn More »

2012

  • Began patient enrollment for Phase 2 AMR-001 trial for prevention of adverse cardiovascular events following a heart attack. Learn More »
  • Expanded NeoStem’s cardiovascular disease intellectual property protection coverage beyond target indication for AMR-001. Learn More »
  • Awarded $595,252 grant from NIAID for the development of VSELTM Technology for radiation exposure. Learn More »
  • Awarded $1.2 million grant from NIH for the first clinical study of VSELTM Technology in humans for periodontitis. Learn More »
  • NeoStem ranked #1 fastest growing company in Tri-State region on Deloitte’s 2012 Technology Fast 500™. Learn More »

2011

  • Held First International Vatican Adult Stem Cell Conference, in partnership with the Vatican’s Pontifical Council for Culture in November. Learn More »
  • Acquired Amorcyte with a Phase 2 ready asset for acute myocardial infarction and a Phase 1 ready asset for congestive heart failure. Learn More »
  • Acquired Progenitor Cell Therapy, whose services include cell therapy, contract manufacturing, and cord blood banking
  • Acquired an 80% ownership of Athelos, a company developing a T-cell therapeutic with potential for a range of auto-immune conditions. Learn More »
  • Awarded and received over $1.7 million from Department of Defense Peer Reviewed Medical Research Program to employ VSEL™ technology to treat osteoporosis and improve bone health. Learn More »

2010

  • Awarded contract with U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center to evaluate the use of adult stem cells for rapid wound healing. Learn More »
  • NeoStem named “Best Stem Cell Company” in The New Economy’s 2010 Biotech Awards. Learn More »
  • Announced breakthrough partnership between the Vatican’s Pontifical Council for Culture and the Stem For Life Foundation. Learn More »
  • PCT announced the first stage of its Allendale facility build complete *

* Prior to NeoStem acquisition For Key Milestones in the history of Progenitor Cell Therapy, please visit pctcelltherapy.com/company/history/